Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2.

Nature communications - 21 Jun 2021

Higuchi Yusuke, Suzuki Tatsuya, Arimori Takao, Ikemura Nariko, Mihara Emiko, Kirita Yuhei, Ohgitani Eriko, Mazda Osam, Motooka Daisuke, Nakamura Shota, Sakai Yusuke, Itoh Yumi, Sugihara Fuminori, Matsuura Yoshiharu, Matoba Satoaki, Okamoto Toru, Takagi Junichi, Hoshino Atsushi

Abstract excerpt

SARS-CoV-2 has mutated during the global pandemic leading to viral adaptation to medications and vaccinations. Here we describe an engineered human virus receptor, ACE2, by mutagenesis and screening for binding to the receptor binding domain (RBD). Three cycles of random mutagenesis and cell sorting achieved sub-nanomolar affinity to RBD. Our structural data show that the enhanced affinity comes from better...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2
Share to COVID-19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19 Drug Treatment

Share to Cricetinae

Share to Molecular Dynamics Simulation

Share to Protein Engineering

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Source

Open in PubMed Open full text

Identifiers

PMID: 34155214
DOI: 10.1038/s41467-021-24013-y
PMCID: PMC8217473

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2.PMID 34155214Read ↗

High affinity modified ACE2 receptors protect from SARS-CoV-2 infection in hamstersSemantic proximity Read ↗

Engineered ACE2 receptor traps potently neutralize SARS-CoV-2Semantic proximity Read ↗

Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.Semantic proximity Read ↗

Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.Semantic proximity Read ↗

Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.Semantic proximity Read ↗

The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2Semantic proximity Read ↗

Comparison of SARS-CoV-2 entry inhibitors based on ACE2 receptor or engineered Spike-binding peptidesSemantic proximity Read ↗

An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variantsSemantic proximity Read ↗

Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants.Semantic proximity Read ↗

Development of a mutant aerosolized ACE2 that neutralizes SARS-CoV-2 in vivo.Semantic proximity Read ↗

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2Semantic proximity Read ↗

Computational and Experimental Identification of Potential Neutralizing Peptides Derived from Human ACE2 Against SARS-CoV-2 InfectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.